Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLCOT-T2D trial of colchicine and aspirin in type 2 diabetes without prior cardiovascular events
2024-516646-19-00Phase 3Authorised
- Sponsor
- Montréal Heart Institute
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of miglitol and aspirin in type 2 diabetes mellitus (T2DM) and cardiac morbidity (4 arms), sponsored by Montréal Heart Institute. Primary endpoint: Major adverse cardiovascular event composite. Planned start Aug 2025; status: authorised.
02
Drugs
miglitolaspirin
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on 2024-516646-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516646-19-00.